Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

NCT00536575 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib
DRUG: Sorafenib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]